论文部分内容阅读
目的 探讨华蟾素对中晚期非小细胞肺癌的治疗效果。方法 将 2 4例中晚期非小细胞肺癌患者随机分成观察组与对照组 ,均用Seldinger支气管动脉插管灌注顺铂、阿霉素和丝裂霉素 ,其中观察组另加入华蟾素。结果 观察组患者临床症状改善率 83.3 % ,近期有效率 (CR +PR) 5 8.3 % ,中位生存 11mo ,均高于对照组。结论 华蟾素不但具有直接抗肿瘤作用 ,而且与化疗药物合用 ,有协同作用 ,且能减轻化疗药物的毒副反应 ,提高生存质量。
Objective To investigate the effect of Cinobufacini on the treatment of advanced non-small cell lung cancer. Methods Twenty-four patients with advanced non-small cell lung cancer were randomly divided into observation group and control group. Seldinger bronchial arterial infusion was used to infuse cisplatin, doxorubicin, and mitomycin. In the observation group, Huaxin was added. Results The improvement rate of clinical symptoms in the observation group was 83.3%, the recent effective rate (CR +PR) was 5 8.3%, and the median survival time was 11 months, which was higher than that of the control group. Conclusion Huachansu not only has a direct anti-tumor effect, but also has a synergistic effect with chemotherapeutic agents, and can reduce the toxicity of chemotherapeutic drugs and improve the quality of life.